Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Frontiers in Immunology|April 13, 2026
Soluble gp130 inhibits Th17 polarization in neutrophilic asthma by blocking IL-6 trans-signaling in dendritic cellsSuhua Zhu, Yun Yao, Tangfeng Lv, et al.Human Cell|October 11, 2021
F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancerYinping Huo, Tangfeng Lv, Mingxiang Ye, et al.The International Journal of Biochemistry & Cell Biology|July 30, 2017
Patterns and functional implications of platelets upon tumor "education"Qun Zhang, Hongda Liu, Qingqing Zhu, et al.Cancer Letters|August 16, 2017
The biology, function and clinical implications of exosomes in lung cancerLi Zhou, Tangfeng Lv, Qun Zhang, et al.Translational Lung Cancer Research|February 17, 2025
Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistanceXin Hua, Xiaodi Wu, Liting Lv, et al.Medical Oncology (Northwood, London, England)|July 14, 2022
c-myc-mediated upregulation of NAT10 facilitates tumor development via cell cycle regulation in non-small cell lung cancerZimu Wang, Yicong Huang, Wanjun Lu, et al.Frontiers in Oncology|February 14, 2022
Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung CancerYangyang Xu, Bing Wan, Suhua Zhu, et al.Medical Oncology (Northwood, London, England)|June 14, 2013
Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transitionLiyun Miao, Suhua Zhu, Yongsheng Wang, et al.Journal of Experimental & Clinical Cancer Research : CR|June 13, 2024
ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophagesXin Hua, Qiuli Xu, Ranpu Wu, et al.Thoracic Cancer|April 7, 2017
Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinomaJiawei Zou, Tangfeng Lv, Suhua Zhu, et al.Pageof 5